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Abstract. Schistosomiasis mansoni is usually a chronic infection that leads to long-term, systemic exposure to schis-
tosome antigens. Experimental Schistosoma mansoni infection is associated with immunoregulatory mechanisms, in-
cluding T regulatory cells (Treg) that may help control morbidity and dampen resistance to re-infection. We now show
that some schistosomiasis mansoni patients have high proportions of CD3+/CD4+/CD25high Treg. On effective treatment
with praziquantel, these high Treg percentages decrease, and fewer of the remaining Treg express CD45RO. The
proportion of Treg in S. mansoni–infected patients is inversely related to their percentage of activated, putative effector
T cells (CD3+/CD4+/CD25medium/HLA-DR+ cells). We conclude some, but not all, schistosomiasis mansoni patients
develop high percentages of circulating Treg, and effective treatment both decreases the levels of these cells and changes
their phenotypes, possibly because of the removal of constant exposure to antigens from intravascular, egg-producing
adult worms.
INTRODUCTION
Schistosoma mansoni is a parasitic trematode that resides in
the mesenteric veins of its human host. After several weeks of
development, female adult schistosomes begin to lay eggs that
have been fertilized by the male worm. The eggs are either
excreted in the feces, to continue the life cycle, or become
impacted in the liver where they induce granuloma formation
that may lead to periportal fibrosis and severe morbidity.1,2
The life span of adult S. mansoni worms is several years, and
infected humans are often repeatedly infected.3–5 Thus, pa-
tients in endemic areas are often exposed to long-term, con-
tinuous systemic exposure to egg and worm antigens.
During chronic infection, egg and worm antigens primarily
provoke Th2 responses such as IgE and interleukin (IL)-5,
some of which have been shown to correlate with resistance
to re-infection.6–9 Our group recently confirmed that eosino-
philia correlates with resistance to re-infection.10 However,
Th2 responses also have been associated with morbidity, and
in some studies, Th1 responses have been associated with
resistance to re-infection.11
Although many situations may lead to host resistance to
re-infection, one such condition seems to be treatment with
praziquantel (PZQ). Immune responses that correlate with
resistance to re-infection, such as increased IgE levels, de-
creased IgG4 levels, and changes in antigen recognition pat-
terns are altered coincident with PZQ treatment.6–9,12–15
Furthermore, schistosome antigen-specific changes in IL-4,
IL-5, IL-10, and IL-13 responses have been observed on treat-
ment.14,16 It is hypothesized that persons who are treated with
PZQ are exposed to bursts of schistosome antigens that may
alter immune responses and eventually increase resistance to
re-infection.17,18
Natural T regulatory cells (Treg)19–21 have a major role in
the control of immune responses in multiple settings, includ-
ing thymic development, autoimmunity, atopic allergy, trans-
plantation, and infectious diseases.22,23 In human paracocid-
iodomycosis, CD4+CD25+ cells (defined as Treg) accumulate
in characteristic granulomatous lesions and exert strong sup-
pressive activity on effector cells, implying that Treg might
contribute to the regulation of these lesions.23 In murine ex-
perimental schistosomiasis, Treg responses control both Th1
and Th2 responses in an IL-10–independent manner24,25 and
are associated with regulation of granuloma formation in
chronic infections.26 To our knowledge, no one has yet re-
ported on Treg in humans with schistosomiasis mansoni.
For a number of years, our group has been studying cohorts
of adult men who are occupationally exposed to S. man-
soni.10,27–30 The initial cohort was men who washed cars in
Lake Victoria near Kisumu, Kenya. More recently, we also
studied men who harvest sand from the bottom of Lake Vic-
toria. Up to one third of these individuals are co-infected with
HIV-1.30 In a previous longitudinal study, we found that some
occupationally exposed men are relatively resistant to re-
infection or develop resistance to re-infection after multiple
treatments and re-infections, whereas others remain highly
susceptible to re-infection.28 In this study, we studied the per-
centages of Treg (defined herein as CD3+/CD4+/CD25high
cells)20 in schistosome-infected patients and those cured of
their infections. We found that some patients exhibit high
percentages of Treg and that these percentages decline after
effective treatment with praziquantel (PZQ). Furthermore,
the phenotypes of Treg change upon treatment, with fewer
Treg expressing CD45RO, a marker associated with T-cell
memory and suppressive activity.
MATERIALS AND METHODS
Study participants. This study was done near Kisumu in
western Kenya. Kisumu is located on the shores of Lake Vic-
toria. The existence of S. mansoni–infected Biomphalaria
sudanica snails has been confirmed (unpublished data) in the
area around the exposure site. The study participants (age,
18–64 years; mean, 28.8 years) were sand harvesters and were
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thus occupationally exposed to schistosome transmission as
they harvested and unloaded sand from the bottom of Lake
Victoria while standing in the water. This study was per-
formed from June 2005 to September 2006. Some of the stud-
ies were cross-sectional, whereas a subgroup of 12 patients
was followed over time, allowing for a follow-up observation
period after PZQ treatment and documented cure.
This study was approved by the Institutional Review
Boards of the University of Georgia and the Centers for Dis-
eases Control and Prevention, the Scientific Steering Com-
mittee of the Kenya Medical Research Institute, and the Na-
tional Ethics Review Board of Kenya. After obtaining in-
formed consent and enrolling the participants, we examined
their stools for S .mansoni eggs and for other helminth ova by
the modified Kato-Katz method (Vestergaard-Frandsen,
Denmark). The participants who were positive for S. mansoni
were treated with 40 mg/kg PZQ; men positive for other hel-
minth ova were treated with 400 mg albendazole.
CD4/CD8 cell counts and whole blood differential count
were determined by FACScount and Coulter Counter analy-
sis, as previously reported.28 After confirming that the par-
ticipants had received HIV-1 counseling and testing through
the Kenyan Ministry of Health Volunteer Counseling and
Testing service, independent HIV-1 screening was performed
on the patients’ plasma samples in our laboratory (Abbott
Determine HIV 1/2; Abbott Japan Co., Minato-Ku, Japan),
and confirmatory tests were done on positives (Unigold; Trin-
ity Biotech, Bray, Ireland).
Previously untreated, egg-positive patients were separated
into two groups (based on their HIV-1 status), and their data
were analyzed separately (Table 1). The mean eggs per gram
feces (EPG) of HIV-seropositive patients (HIV+) was lower
(P < 0.05) than that of HIV seronegative (HIV−) patients
(Table 1), consistent with our previous findings in occupa-
tionally exposed adult men with exceptionally high egg
counts.30 As expected, the mean CD4+ cell count was lower
and the CD8+ cell count higher in the S. mansoni–infected
patients who were co-infected with HIV-1 than in those with-
out HIV-1 infection (Table 1).
Cell surface staining and flowcytometric analysis. Blood
was collected by venipuncture into EDTA-coated glass tubes
(BD Vacutainer System, Franklin Lakes, NJ). To identify
Treg in peripheral blood, anti-CD3 (fluorescein isothiocya-
nate [FITC] or allophycocyanin [APC] conjugated, clone:
UCHT1; e-Bioscience, San Diego, CA), anti-CD4 (FITC or
PerCP conjugated, clone: OKT-4; e-Bioscience), and anti-
CD25 (PE conjugated, clone:BC96; e-Bioscience) were used.
Because anti-FOXP3 antibodies were not commercially avail-
able at the beginning of this study, we defined Treg cells as the
CD3+/CD4+/CD25high population.31–37 Gating to separate
CD25neg cells from CD25medium cells was based on fluo-
rescence minus one (FMO)–stained samples.38 The gating
used to distinguish CD25high from CD25medium cells was de-
termined by examining the CD4/CD25 dot plots from all
patients studied and setting thresholds that most often differ-
entiated these subpopulations (CD25low, CD25medium,
CD25high).20,32 These thresholds (Figure 1) were determined
before any phenotypic analyses, were used for all analyses in
this study and are based on those used throughout the litera-
ture.32–37 To examine phenotypic subsets of Treg, the follow-
ing antibodies were used: anti-PD-1 (CD279; FITC conju-
gated, clone: MIH4; e-Bioscience), anti-CD152 (APC conju-
gated, clone: BNI3; BD Pharmingen, San Diego, CA), anti-
C D 4 5 R O ( A P C c o n j u g a t e d , c l o n e : U C H L 1 ; B D
Pharmingen), and anti-HLA-DR (APC conjugated, clone:
LN3; e-Bioscience). FMO-stained samples were used to sepa-
rate positive from all negative populations.38
Statistical analysis. Statistical analyses were performed us-
ing GraphPad PRISM version 3.0 for Windows (Graph Pad
Software, San Diego, CA) and Microsoft Excel. The Mann-
Whitney U test was used for nonparametric group compari-
sons. Wilcoxon matched pairs signed rank test was used to
analyze the changes of Treg percentages and phenotypes be-
fore and after PZQ treatment. Spearman rank test was used
to examine possible correlations between EPG and Treg per-
centages and the percentages of Treg versus activated T ef-
fector cells. P values of 0.05 were considered to indicate sta-
tistical significance.
RESULTS
Proportion of Treg in schistosome-infected patients. Schis-
tosome-infected patients who had not been treated previously
and who were HIV-1 seronegative (N  48) had a mean
percentage of Treg (CD3+/CD4+/CD25high cells) of 4.7%
(SD  3.5). For patients who had not been treated with PZQ
before but were HIV-1 seropositive (N  7), it was 5.5%
(SD  3.7). Because there was no significant difference in the
%Treg between these HIV-1(+) and HIV-1(−) groups, they
are plotted together in Figure 2. Among these egg-positive
patients, there were 17 patients (31%) who had what we con-
sidered high percentages (5%–10%) of Treg and 5 (9%) who
had very high Treg percentages (> 10%; Figure 2). Average
percentages of circulating CD4+/CD25high Treg in normal in-
dividuals are 1%–3%.20,39 Thus, 40% of patients with patent
S. mansoni infections exhibited high or very high percentages
of circulating Treg.
Changes of Treg percentages and phenotypes after
PZQ treatment. To examine the effect of treatment on Treg
populations in persons with schistosomiasis, a subgroup of
patients was longitudinally followed before and after treat-
ment with PZQ. The time between the pre-treatment evalu-
ation and the re-evaluation on cure ranged from 8 to 14
months (mean ± SD; 9.4 ± 1.8 months). These studies were
performed only on individuals who were actively infected at
the first examination, had not been treated previously, were
cured on treatment (went to zero EPG and remained negative
until at least the time of the second phenotypic analysis), and
were HIV-1(−) (Figure 3). Before treatment, the mean per-
centage of Treg was 6.1% (SD  4.2); this value decreased to
3.7% (SD  1.2) after treatment (P  0.05), showing a sig-
nificant impact of effective treatment. PD-1 (CD279) was ex-
pressed on 12.1% Treg (SD  7.4) before treatment, and this
TABLE 1
Quantification of S. mansoni eggs and CD4 and CD8 cells in un-
treated schistosomiasis patients by HIV status
Patient group No. of patients
Mean value ± SD
EPG* CD4 count CD8 count
HIV (−)† 48 1,050 (1,452) 658 (248)‡ 489 (298)‡
HIV (+)† 7 330 (527)§ 303 (185) 934 (447)
* Schistosoma mansoni EPG.
† HIV(−), HIV-1 seronegative; HIV(+), HIV-1 seropositive.
‡ P < 0.01 compared with HIV(+) group.
§ P < 0.05 compared with HIV(−) group.
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increased, but not significantly, to 18.9% (SD  7.6) on cure
(Figure 3B; P  0.07). CD45RO was expressed on 85.9% of
Treg before treatment (SD  6.5) but occurred on only
65.9% (SD  20.4) of Treg after treatment and cure (P 
0.002; Figure 3C). Thus, Treg expression of CD45RO, which
is often associated with T-cell memory, was significantly de-
creased after treatment. Multiple studies have shown that
∼85% of Treg in most human subjec t s express
CD45RO.20,39–-41 In cross-sectional studies, 79% of Treg cells
in our HIV(−) patients (N  48) expressed CD45RO. We
also tested cells from most of our HIV(−) patients for expres-
sion of HLA-DR by Treg, which is indicative of T-cell acti-
vation in humans,20,42,43 and found that 23% of Treg were
HLA-DR+ (N  36). In addition, we tried to assess the ex-
pression of CD152 (CTLA-4) on Treg, but these assays failed
to detect significant surface membrane expression of this
marker (usually < 1% Treg were surface-CD152+, data not
shown).
Treg and the intensity of infection. We analyzed the Treg
proportions in the peripheral blood of patients before treat-
ment with PZQ who were HIV-1(−) (N  48) in relationship
to the intensity of infection, based on the number of EPG
(Figure 4). There was no statistically significant correlation
between the generally high intensities of infection in this co-
hort (Table 1; Figure 4) and the percentages of Treg in the
circulation (P  0.19).
Relationship of Treg percentages to peripheral blood eosi-
nophilia and activated CD4+ CD25medium T cells. These west-
ern Kenyan patients have elevated peripheral blood eosino-
philia that correlates with increased resistance to re-
infection,10 consistent with earlier studies that human
eosinophils may be effector cells against schistosomes.44,45
Therefore, we examined the relationship between the per-
centages of Treg and eosinophilia. We did not, however, find
any correlation between these two cell populations in the
peripheral blood of our patients (N  47; r  0.02; P  0.91).
FIGURE 1. Flow cytometry analysis of whole blood cells stained with anti-CD3, anti-CD4, and anti-CD25 was used to define
CD3+CD4+CD25high cells. A, CD3+/CD4+ lymphocytes were gated and analyzed for positive CD25 expression using a threshold (B) based on the
fluorescence minus one (FMO) “no CD25-PE” controls.38 After examination of the scatter plots of all patients, a threshold was set between
CD25medium and CD25high cells [dotted line in A]. This threshold, and that provided by the FMO controls, was then used throughout for all
analyses. C, Histogram of CD25-PE spectrum showing where the CD25high gate was set throughout.
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By using CD4/CD25 gating strategies based on FMO and
examining all patient data, we identified both the Treg popu-
lation (CD25high) and an activated, putative effector T-cell
population (CD25medium).39 When the proportions of these
two CD4+ populations were further analyzed by comparing
the percentage of Treg against the percentage of presumed
effector T cells that were activated (CD4+/CD25medium,
HLA-DR+), we found a statistically significant negative cor-
relation between these two populations of T lymphocytes
(Figure 5). Thus, those patients who had higher percentages
of Treg had lower percentages of activated effector T cells
(N  35; r  −0.37; P  0.03). This relationship was not
found when Treg were analyzed against effector T-cell popu-
lations (CD4+/CD25medium) that were not activated (i.e., did
not express HLA-DR; data not shown). The reciprocal rela-
tionship of increased Treg and decreased activated T effector
cells needs further study at the functional level in this chronic
antigen exposure condition.
DISCUSSION
Accumulating data on naturally occurring Treg indicate
that they are involved in immune regulation of various con-
ditions such as autoimmune diseases, graft organ transplan-
tation, and infectious diseases.22,46 In infectious diseases, Treg
may be induced in antigen-specific manner and may suppress
tissue destruction resulting from immune responses.23 In ex-
perimental schistosomiasis and the schistosome egg injection
model, Treg is reported to control both Th1 and Th2 aspects
of the immune response.25 In this study, we examined Treg in
schistosome-infected patients and analyzed them before and
after effective treatment with the antischistosomal drug PZQ.
We found that the mean percentage of Treg in the peripheral
blood of our patients was ∼5%, which is more than double
levels reported in the literature for persons who do not have
schistosomiasis.20,39 Paired data analysis showed a statistically
significant decrease in Treg percentages on treatment and
cure of schistosomiasis (Figure 3). We hypothesized that the
removal of chronic, systemic exposure to schistosome anti-
gens through PZQ treatment led to the decrease. In contrast,
Treg percentages did not correlate with intensity of infection
(Figure 4). However, this analysis may be somewhat con-
founded by the extremely high intensities of infection ob-
served in the occupationally exposed cohort studied.
PD-1 (CD279) is a surface receptor that, along with one of
its ligands PD-L1, is involved in regulating T-cell activa-
tion.47,48 In chronic viral infections, this pathway can inhibit
CD8 T-cell responses.49,50 PD-L1 ligation of PD-1 can also
induce apoptosis of T cells.51 In schistosome infection, inhi-
bition of the PD-1/PD-L1 pathway restores the suppressed
response of T cells to adult worm antigen.52 In addition, mice
with severe schistosome-related morbidity have fewer T cells
that express PD-1 than mice with less severe disease.53 In this
human study, PD-1 was expressed on a mean of 14.5% of
Treg cells in the cross-sectional, untreated HIV-1(−) patients,
(data not shown), and on 12.1% of the Treg of the 12 patient
subgroup before treatment. On treatment and cure, whereas
the mean percentage of Treg went down (Figure 3A), the
percentage of the Treg that expressed PD-1 increased in 8 of
12 men (Figure 3B). Where it occurred, increased PD-1 ex-
pression by Treg may have contributed to the decrease in
Treg percentages through the induction of apoptosis through
PD-L1 ligation.51
A mean of 79% of the circulating Treg of all untreated,
HIV-1(−) patients were positive for CD45RO, a memory cell
marker consistently expressed on a very high percentage of
Treg.20,39–41 Among CD4+/CD25+ T cells, CD45RO+ cells
have a suppressive phenotype.54 Interestingly, in the 12 pa-
tients followed before treatment and after cure, a significant
decrease was observed in the percentage of Treg that express
CD45RO (Figure 3C). This could indicate that not only did
the overall percentage of Treg decrease on cure, but those
that remain after treatment and cure were less suppressive
than those present before treatment.54 However, because no
functional studies were done in this investigation, it is impos-
sible to evaluate this hypothesis at this time.
We observed an intriguing relationship between CD3+/
CD4+/CD25high Treg cells and CD3+/CD4+/CD25medium/
HLA-DR+ activated, putative effector T cells in the circula-
tion of actively infected schistosomiasis mansoni patients
(Figure 5). Our data indicated a reciprocal relationship be-
tween these two populations of cells. Although this is only a
correlation, and not necessarily a cause and effect relation-
ship, it could mean that a higher proportion of circulating
Treg leads to a lower proportion of activated effector T cells.
This relationship did not exist if the CD4+/CD25medium T cells
were not activated (i.e., did not co-express HLA-DR). Un-
fortunately, it was not possible to examine this relationship
FIGURE 2. Percentages of Treg (CD3+CD4+CD25high cells) in the
peripheral blood of untreated, schistosome-infected patients. Hori-
zontal dashed bars indicate stratification levels of patients with < 5%,
5%–10%, or > 10% Treg in their circulation.
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after treatment and cure because of an inadvertent resetting
of the FL4 gain in the middle of the study to a point that
discrimination of HLA-DR positivity could not be deter-
mined. In this descriptive study, we did not attempt to exam-
ine the functional role of these populations against another,
because this would likely require a level of fine cell sorting
that is not available to us in the Kisumu laboratory. In con-
trast to this potential regulatory relationship between Treg
and activated effector CD4 T cells, we did not find any rela-
tionship between the percentages of circulating Treg and pe-
ripheral blood eosinophilia.
In this study, we used a CD25high gate on CD3+/CD4+ T
cells to identify Treg because anti-FOXP3 antibodies were
not commercially available when we began the study. How-
ever, there are reports that show that Treg can be
CD4+CD25−,20,54 so our study may not be inclusive of all
natural Treg. In fact, in murine schistosome infections, the
reliability of CD25 expression as a marker of Treg cell de-
creased in chronic infections because Foxp3 negative
CD4+CD25+ cells increased.24 Because our study has dealt
with adults from a highly endemic area where they are ex-
posed daily to the threat of infection through their occupa-
tion, we assume that they have chronic infections. Neverthe-
less, we realize that the percentage of Treg cells may differ
when Treg are defined by measuring FOXP3 positive cells
instead of CD25high cells, and acknowledge that as better defi-
nitions of human Treg continue to develop, studies should be
FIGURE 3. Changes in levels of Treg and Treg subsets in 12 patients before treatment and after treatment and cure: (A) Treg; (B) PD-1
expression by Treg; (C) CD45RO expression by Treg.
FIGURE 4. No relationship between Treg percentages and infec-
tion intensities. Eggs per gram of feces (EPG) of untreated, HIV-1-
negative patients compared with their percentage of Treg.
FIGURE 5. Inverse relationship of Treg and activated, putative
effector T cells (CD4+CD25mediumHLA-DR+ cells) in the peripheral
blood of untreated, HIV-1 seronegative, schistosome-infected pa-
tients.
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undertaken which incorporate the most complete set of mark-
ers available.
This study is the first documentation of cells with a Treg
phenotype in human schistosomiasis. The main findings of the
study are that some, but not all, actively infected patients
exhibit high Treg percentages, and that cured patients exhibit
lower proportions of these cells. Furthermore, the percentage
of Treg is inversely correlated with the percentage of acti-
vated effector CD4 T cells. In addition, we found that some
subsets of Treg were altered upon cure with PZQ. Specifi-
cally, lower percentages of Treg expressed the memory (and
suppressive) phenotype as indicated by the presence of fewer
Treg and fewer of those that expressed CD45RO. Overall,
these data indicated that Treg percentages are increased in
some people with schistosomiasis mansoni, and when this oc-
curs it can be reversed by treatment and cure. It will be of
interest to see whether 1) resistance to re-infection; 2) severe
or subtle morbidity; 3) humoral immune responses; or 4) cel-
lular immune responses are associated with differences in cir-
culating Treg proportions. These relationships are now being
evaluated through ongoing longitudinal studies in larger co-
horts of adult men in western Kenya. If any of these relation-
ships exist, it should be possible to determine how treatment
and cure alters them, potentially leading to an increase in
resistance because of removal of immunoregulation.
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